MedTrace Logo

Safety and Efficacy of WIN-901X in Asthma

NCT01820481 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2013-12-09

No results posted yet for this study

Summary

This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.

Conditions

Interventions

DRUG

WIN-901X dose level 1

100mg Bid, PO, 12weeks

DRUG

WIN-901X dose level 2

200mg Bid, PO, 12weeks

DRUG

WIN-901X dose level 3

300mg Bid, PO, 12weeks

DRUG

Placebo

Bid, PO, 12weeks

Sponsors & Collaborators

  • Whanin Pharmaceutical Company

    lead INDUSTRY

Principal Investigators

  • Park Hae Sim, M.D., Professor · Yes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01820481 on ClinicalTrials.gov